These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32484812)

  • 1. Mitotic activity index and CD25+ lymphocytes predict risk of stage progression in non-muscle invasive bladder cancer.
    Lillesand M; Kvikstad V; Mangrud OM; Gudlaugsson E; van Diermen-Hidle B; Skaland I; Baak JPA; Janssen EAM
    PLoS One; 2020; 15(6):e0233676. PubMed ID: 32484812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic comparison of proliferation markers and World Health Organization 1973/2004 grades in urothelial carcinomas of the urinary bladder.
    Mangrud OM; Gudlaugsson E; Skaland I; Tasdemir I; Dalen I; van Diermen B; Baak JP; Janssen EA
    Hum Pathol; 2014 Jul; 45(7):1496-503. PubMed ID: 24796506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
    Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
    J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer.
    Culpan M; Turan T; Ozkanli SS; Zenginkinet T; Kazan O; Ucar T; Atis G; Caskurlu T; Yildirim A
    J Cancer Res Ther; 2021; 17(2):434-442. PubMed ID: 34121689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder.
    Bol MG; Baak JP; Rep S; Marx WL; Kruse AJ; Bos SD; Kisman O; Voorhorst FJ
    Urology; 2002 Dec; 60(6):1124-30. PubMed ID: 12475695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
    Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
    Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks.
    Bol MG; Baak JP; van Diermen B; Buhr-Wildhagen S; Janssen EA; Kjellevold KH; Kruse AJ; Mestad O; Øgreid P
    J Clin Pathol; 2003 Jun; 56(6):447-52. PubMed ID: 12783972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder.
    Gontero P; Casetta G; Zitella A; Ballario R; Pacchioni D; Magnani C; Muir GH; Tizzani A
    Eur Urol; 2000 Sep; 38(3):287-96. PubMed ID: 10940702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferation and immunohistochemistry for p53, CD25 and CK20 in predicting prognosis of non-muscle invasive papillary urothelial carcinomas.
    Kvikstad V; Lillesand M; Gudlaugsson E; Mangrud OM; Rewcastle E; Skaland I; Baak JPA; Janssen EAM
    PLoS One; 2024; 19(1):e0297141. PubMed ID: 38277354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of preoperative circulating CD8-positive lymphocytes in the urinary bladder recurrence of urothelial carcinoma.
    Lin CT; Tung CL; Tsai YS; Shen CH; Jou YC; Yu MT; Wu SF
    Urol Oncol; 2012 Sep; 30(5):680-7. PubMed ID: 21420334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer.
    Liu K; Zhao K; Wang L; Sun E
    Pathol Res Pract; 2018 Aug; 214(8):1074-1080. PubMed ID: 29803657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer.
    Ayari C; LaRue H; Hovington H; Caron A; Bergeron A; Têtu B; Fradet V; Fradet Y
    Hum Pathol; 2013 Aug; 44(8):1630-7. PubMed ID: 23574787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study.
    Kobayashi S; Fujii Y; Koga F; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
    Urol Oncol; 2014 Jan; 32(1):38.e29-36. PubMed ID: 23702087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
    Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
    Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated pre-existing lymphocytic infiltrates in tumour stroma predict poor prognosis in resectable urothelial carcinoma of the bladder.
    Wang B; Xie S; Bi J; Liu Z; Zeng H; Huang H; Xue M; He Z; Yang M; Yu H; Huang J; Lin T
    Histopathology; 2019 Sep; 75(3):354-364. PubMed ID: 30653702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.